TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05494957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: New regimen(BdqCfzLzd+XY)
Description: The basic regimen consists of bedaquiline, clofazimine, linezolid, and 2-3 drugs such as amikacin and tigecycline are selected according to the drug use history and in vitro culture drug sensitivity results to form the regimen, and the treatment period is usually more than 12 months, and the doses of various drugs are used for the regular drug use.
Study: NCT06292949

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resistant starch
Description: Constipated patients take 1 pack of resistant starch (20g/pack) daily for 14 days
Study: NCT06493825

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aurora Mindfulness app versus sham
Description: It would either immersive virtual reality exposure for the experimental group or non-immersive virtual reality exposure for the placebo group.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Aurora Mindfulness app versus sham
Description: It would either immersive virtual reality exposure for the experimental group or non-immersive virtual reality exposure for the placebo group.
Study: NCT06149897

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: Non invasive brain stimulation with sham and active comparators

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: Non invasive brain stimulation with sham and active comparators
Study: NCT06191055

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beta Alanine high dose
Description: 4 intakes of 5 g of beta alanine every 3 hour.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beta Alanine low dose
Description: 4 intakes of 2.5 g of beta alanine every 3 hour.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: 4 intakes of 2.5 g of wheat semolina every 3 hour.
Study: NCT06175377

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention
Description: A percutaneous coronary intervention for chronic total occlusion lesion with at least one implanted coronary stent will be performed as part of routine care.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Description: A percutaneous coronary intervention for chronic total occlusion lesion with at least one implanted coronary stent will be performed as part of routine care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Short dual Aspirin/Clopidogrel therapy
Description: Aspirin will be prescribed as part of the patient's normal course of care, according to current recommendations. The second antiplatelet agent will be clopidogrel, the duration of which will vary according to the randomization group of each patient included. Patients will be treated for 1 month.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Long dual Aspirin/Clopidogrel therapy
Description: Aspirin will be prescribed as part of the patient's normal course of care, according to current recommendations. The second antiplatelet agent will be clopidogrel, the duration of which will vary according to the randomization group of each patient included. Patients will be treated for 6 to 12 months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Follow-up visit at 1 month
Description: At 1 month following the inclusion a visit or a phone call with the referring cardiologist will be organized.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow-up visit at 1 month
Description: At 1 month following the inclusion a visit or a phone call with the referring cardiologist will be organized.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Follow-up visit at 6 months
Description: At 6 months following the inclusion a visit or a phone call with the referring cardiologist will be organized.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Follow-up visit at 12 months
Description: At 12 months following the inclusion a visit or a phone call with the referring cardiologist will be organized.
Study: NCT05114486

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Pilocarpine Ophthalmic administered with the Optejet dispenser
Description: Pilocarpine 2% ophthalmic spray administered with the Optejet dispenser
Study: NCT06459713

Intervention type: DIAGNOSTIC_TEST
Intervention: multiplex respiratory polymerase chain reaction test
Description: According to our hospital policy, nasopharyngeal swab samples are collected by the clinicians and transported to the Clinical Microbiology Laboratory of the hospital in 10 minutes. The samples are analyzed in 2 hours and the samples were measured by Thermo Fisher / Applied Biosystems Quant Studio-5 for reverse transcription-polymerase chain reaction (RT-PCR) testing to detect multiplex respiratory agents

Intervention type: DIAGNOSTIC_TEST
Intervention: multiplex respiratory polymerase chain reaction test
Description: According to our hospital policy, nasopharyngeal swab samples are collected by the clinicians and transported to the Clinical Microbiology Laboratory of the hospital in 10 minutes. The samples are analyzed in 2 hours and the samples were measured by Thermo Fisher / Applied Biosystems Quant Studio-5 for reverse transcription-polymerase chain reaction (RT-PCR) testing to detect multiplex respiratory agents
Study: NCT04691128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: After induction, anesthesia will be maintained with 0.8-1.3 MAC desflurane and 0.05-0.2 μg/kg/min remifentanil.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: After induction, anesthesia will be maintained with 6-8 mg/kg/h propofol and 0.05- 0.2 μg/kg/min remifentanil
Study: NCT05731700

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug Eluting Balloon
Description: PCI of in-stent restenosis
Study: NCT05114486

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo administered with the Optejet dispenser
Description: Vehicle ophthalmic solution administered with the Optejet dispenser
Study: NCT04851132

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: IMRT (Intensity Modulated RT) or 3D-CRT (three-dimensional conformal radiotherapy); 95% PGTV 59.92Gy/2.14Gy/28f; 95% GTVnd 59.92Gy/2.14Gy/28f; 95% PTV 50.40Gy/1.80Gy/28f; 5 days a week; 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1000 mg, intravenously (IV), on Day 1 of radiotherapy, every 3 weeks for up to 18 administrations.
Study: NCT05669118

Intervention type: PROCEDURE
Intervention: Tooth Autotransplantation
Description: Place another tooth in the place of the newly extracted tooth in the same patient.

Intervention type: PROCEDURE
Intervention: Immediate implant
Description: Place a dental implant immediately after tooth extraction.
Study: NCT06225492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DaxibotulinumtoxinA 15 units
Description: Subjects will be treated with 15 units of daxibotulinumtoxinA per platysmal band

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DaxibotulinumtoxinA 20 units
Description: Subjects will be treated with 20 units of daxibotulinumtoxinA per platysmal band
Study: NCT05762367

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 3T MRI with Gadobutrol injection
Description: MRI will be performed in all participants before and after Gadobutrol injection

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 3T MRI with Gadobutrol injection
Description: MRI will be performed in all participants before and after Gadobutrol injection
Study: NCT05370898

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Caltrate D
Description: Caltrate D is allowed for basic treatment when the patient is diagnosed with primary osteoporosis (Kidney Yang Deficiency Syndrome).Take it continuously for 3 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caltrate D
Description: Caltrate D is allowed for basic treatment when the patient is diagnosed with primary osteoporosis (Kidney Yang Deficiency Syndrome).Take it continuously for 3 months.
Study: NCT05394753

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unified Protocol for mood disorders
Description: The group-based UP is structured and manualized and consists of 9 1.5 hours weekly sessions (90-min, 18 participants in each group). The group-based UP is a course consisting of components of psycho-education about mood disorders, cognitive and behavioural skills, and relapse prevention and is adapted for the non-clinical population in the current study. The UP will be led and delivered by trained therapists.
Study: NCT05370898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese medicine prescription
Description: The Chinese medicine application prescription is composed of Rhizoma Drynariae 12g, psoralen 10g, dog ridge 10g, medlar 10g, raw oyster 10g, ginseng 6g, Panax notoginseng 3g, Amomum villosum 6g.Patients take 200ml each time, twice a day. Treatment duration are 3 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is simulate granule of Chinese medicine application prescription. Patients take 200ml each time, twice a day. Treatment duration are 3 months.
Study: NCT04985045

Intervention type: OTHER
Intervention: Evaluation
Description: Individuals' menstrual status, pain, menstrual symptoms and genital hygiene behaviors will be evaluated.

Intervention type: OTHER
Intervention: Evaluation
Description: Individuals' menstrual status, pain, menstrual symptoms and genital hygiene behaviors will be evaluated.
Study: NCT05215028

Intervention type: DEVICE
Intervention: web-application
Description: web application multi-domain familial digital health record PRO The aim is to help for early screening of neurodevelopmental disorders of toddler after birth to 3 years of age and mother's postnatal depression, to improve vaccinations rate of toddlers and to provide advice to parents for child development.
Study: NCT00236379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Target oral dose of 20 milligrams per day for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: Target oral dose of 6 milligrams per day for for 6 months
Study: NCT04706897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine, ketamine and lidocaine
Description: A loading infusion of syringe (B) containing the a mixture \[dexmedetomidine (2 µg/ml), ketamine (0.5 mg /ml) and lidocaine (4 mg /ml)\] was started at rate of 0.2 ml/kg/h ten minutes before induction. Then anesthesia was induced with 2 mg/kg IBW of propofol, patients were intubated with the aid of 0.5 mg/kg IBW atracurium and received 0.1ml/kg from syringe (D) containing normal saline (as masking for fentanyl in the control group).

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Normal saline
Description: A loading infusion of the 50 ml syringe (A) containing normal saline was started at rate of 0.2 ml/ kg/hr ten minutes before induction (as masking for mixture in group S). Then anesthesia was induced with 2 mg/kg ideal body weight (IBW) of propofol , patients were intubated with the aid of 0.5 mg/kg IBW atracurium and received 0.1ml/kg from syringe (C) containing fentanyl (1mic/kg of IBW).
Study: NCT06071897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: monoclonal antibodies GD2
Description: Main target of this trial is to estimate tolerability and toxicity of combination of standard chemotherapy (N5 and N6) with anti-GD2 MAB~N5Q. N5 (see above) Dinutuximab beta 10 mg/m2 i.v., days 5-9\*~N6Q. N6 (see above) Dinutuximab beta 10 mg/m2 i.v., days 6-10\*~G-CSF (granulocyte colony-stimulating factor) 5 mcg/kg s.c. on day 9 until the ANC is more than 2000 /ml or until counts have recovered for the next cycle of therapy
Study: NCT04922229

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RCT
Description: This is the standard of care for this diagnosis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulpotomy
Description: For cases with normal apical tissues, pulpotomy using tricalcium silicates has been shown to have high clinical success. Either partial or complete pulpotomy will be performed depending on the size of pulp exposure.
Study: NCT04839822

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: edupression.com®
Description: Edupression.com® is an evidence-based self-help program that was developed for the treatment of mild to moderate unipolar depression. It is based on two core foundations, psychoeducation with elements of cognitive behavior therapy (CBT) and a mood chart. Both foundations are registered as a medical product. As such, detailed risk management documentation includes probability and severity of adverse events. Moreover, detailed strategies such as warnings were implemented in the software and documented accordingly.~It can be used on a PC as well as on mobile devices (browser, App) at any time.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health tips
Description: Interventions that do not directly target depression: general health tips (diet, lifestyle, smoking, etc.), occupational health interventions (back pain prevention, breaks,...), etc.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Surveys
Description: Quizzes and surveys for course monitoring (including suicidality), but without extensive reports.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Popular psychological interventions
Description: Popular psychological interventions, which have not been shown to be effective in studies: Affirmation phrases, motivational sayings and quotes (known also from calendars), tests (e.g., Rorschach interpretation), exercises (emotion recognition of faces), multimedia content (pleasant music, landscape images, interviews of famous people with depression), etc.
Study: NCT05691751

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: primary unilateral total knee arthroplasty with limited application of tourniquet
Description: the tourniquet will be applicated around the proximal thigh in all patients before the incision, all patients will undergo primary unilateral TKA by the same surgeon using the medial para-patellar approach, and the prostheses used in all patients will be cruciate scarifying cemented DePuy Synthes PFC Sigma without resurfacing of the patella, intramedullary guides will be used for the femoral and tibial cuts as seen appropriate by the surgeon, however, the application time of the tourniquet during surgery will be as the allocation of each patient imply.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: primary unilateral total knee arthroplasty with full application of tourniquet
Description: the tourniquet will be applicated around the proximal thigh in all patients before the incision, all patients will undergo primary unilateral TKA by the same surgeon using the medial para-patellar approach, and the prostheses used in all patients will be
Study: NCT05057689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Dexmedetomidine (4 mcg/kg)
Description: Dexmedetomidine 100 mcg/mL (concentration of 200 mcg/2 mL) will be atomized for intranasal administration at a dose of 4 mcg/kg (0.04 mL/kg) according to a weight-based dosing chart prior to laceration repair. The maximum dose will be 200 mcg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Fentanyl (2 mcg/kg)
Description: Fentanyl 50 mcg/mL (concentration of 100 mcg/2 mL) will be atomized for intranasal administration at a dose of 2 mcg/kg (0.04 mL/kg) according to a weight-based dosing chart prior to laceration repair. The maximum dose will be 100 mcg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Midazolam (5 mg/kg)
Description: Midazolam 5 mg/mL (concentration of 10 mg/2 mL) will be atomized for intranasal administration at a dose of 0.3 mg/kg (0.06 mL/kg) according to a weight-based dosing chart prior to laceration repair. The maximum dose will be 10 mg.
Study: NCT05833477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin
Description: Recombinant human erythropoietin treatment three times per week for three weeks
Study: NCT05728736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant 25 mg
Description: Lemborexant 25mg will be taken nightly for two consecutive nights.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be taken nightly for two consecutive nights
Study: NCT05426408

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Cardiac magnetic resonance imaging to study coronary microvascular dysfunction
Description: Myocardial perfusion mapping will be investigated after administration of adenosine
Study: NCT06028789

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample test
Description: The following groups of biomarkers will be examined:~* standard panel of inflammation markers: CRP, PCT, IL-6, Leukocyte count, differential blood count~* microbiology cultures according to the clinical status~* serum biomarkers: sCD64, sTREM-1, calprotectin, pentraxin 3~* flow cytometry: HLA-DR, CD14, CD16, CD40, CD45, CD64, CD163 expression on granulocytes and monocytes~* cell function assay: IL-18 and IFN-γ~* hematology: ICIS, Neutrophil-to-lymphocyte ratio - examined together with conventional hematological parameters.~The schedule of blood sample taking will be as follows:~A. the study group: preoperatively (T-1), 1st postoperative day (T1), 3rd postoperative day (T2), 7th postoperative day (T3), 10th postoperative day (T4)~B. the control group: at admission or the next day (T1), 3rd day of hospital stay (T2), 7th day of hospital stay (T3), 10th day of hospital stay (T4)

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample test
Description: The following groups of biomarkers will be examined:~* standard panel of inflammation markers: CRP, PCT, IL-6, Leukocyte count, differential blood count~* microbiology cultures according to the clinical status~* serum biomarkers: sCD64, sTREM-1, calprotectin, pentraxin 3~* flow cytometry: HLA-DR, CD14, CD16, CD40, CD45, CD64, CD163 expression on granulocytes and monocytes~* cell function assay: IL-18 and IFN-γ~* hematology: ICIS, Neutrophil-to-lymphocyte ratio - examined together with conventional hematological parameters.~The schedule of blood sample taking will be as follows:~A. the study group: preoperatively (T-1), 1st postoperative day (T1), 3rd postoperative day (T2), 7th postoperative day (T3), 10th postoperative day (T4)~B. the control group: at admission or the next day (T1), 3rd day of hospital stay (T2), 7th day of hospital stay (T3), 10th day of hospital stay (T4)

Intervention type: PROCEDURE
Intervention: Thoracic Aortic Surgery
Description: Scheduled surgical intervention, i.e. replacement of pre-specified part of thoracic aorta by a vascular prosthesis.
Study: NCT06173479

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HeBSaPU
Description: HeBSaPU training content explains the definition of pesticides, their way of entry into the body, and their health effects. Personal protective equipment, personal hygiene behaviors, and safe behaviors regarding the correct and safe use of pesticides were mentioned.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HeBSaPU
Description: HeBSaPU training content explains the definition of pesticides, their way of entry into the body, and their health effects. Personal protective equipment, personal hygiene behaviors, and safe behaviors regarding the correct and safe use of pesticides were mentioned.
Study: NCT04549896

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT scan
Description: Surgeon will perform a CT scan before the surgery procedure (CTO PCI) in order to increase the success rate of the surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No CT scan
Description: The surgery procedure (CTO PCI) will be performed following the standard of care, meaning that the surgeon will not perform a CT scan before the surgery procedure.
Study: NCT06387628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LM-108
Description: LM-108, 10mg/kg, d1, q6w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LM-108
Description: LM-108, 10mg/kg, d1, q6w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab, 240 mg, d1, q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab, 240 mg, d1, q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Eribulin 1.4 mg/m2, d1, 8 , q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Nab paclitaxel 125 mg/m2, d1, 8 , q3w
Study: NCT05165927

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BFR
Description: BFR cuffs will be used at home during specified exercises in addition to SOC for post hip scope PT.
Study: NCT06003920

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Process group
Description: The medical student process group served as a space for students to gain increased self-awareness through guided exploration of the psychodynamic processes.
Study: NCT05405998

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proactive care pathway
Description: Patient participation in a specific therapeutic education program, as soon as the therapeutic decision is made.~The reinforced cooperation of the expert centers with the homecare providers on 2 different times:~1. before the installation of the pump, i.e. before the episode of hospitalization dedicated to the starting of the treatment;~2. after the installation of the pump following the above mentioned hospitalization.
Study: NCT05867160

Intervention type: OTHER
Intervention: ASM as adjunctive therapy
Description: ASM approved as adjunctive therapy
Study: NCT05810766

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mobilization with movement
Description: MWM at glenohumeral joint and then we will add progression by adding glides at sternoclavicular and acromioclavicular joint.5 sets of painless glides of 10 repetitions will be given, with 3-minute rest between sets.

Intervention type: OTHER
Group type: OTHER
Intervention: conventional physical therapy
Description: Hot pack for 15 minutes
Study: NCT05166330

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketofol equal ratio
Description: 5mg/ml10 mL propofol (100 mg) will be mixed with 2 mL ketamine (100 mg) and then diluted to a total volume of 20 mL to have a final concentration of 5 mg/mL propofol and 5 mg/mL ketamine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketofol 1:3 ratio
Description: 15 mL propofol (150 mg) will be mixed with 1 mL ketamine (50 mg) and then diluted to a total volume of 20 mL to have a final concentration of 7.5 mg/mL propofol and 2.5 mg/mL ketamine).
Study: NCT04716660

Intervention type: OTHER
Intervention: Sensory block level check
Description: Patients will have their sensory block level checked multiple times following administration of their epidural bolus for labor analgesia.
Study: NCT06315426

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GR1802 injection
Description: Recombinant fully human anti-IL4Rα monoclonal antibody drug.